Zacks Research Analysts Lower Earnings Estimates for CRL

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Charles River Laboratories International in a research report issued to clients and investors on Thursday, April 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.06 for the quarter, down from their prior forecast of $2.07. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q2 2025 earnings at $2.29 EPS, Q3 2025 earnings at $2.40 EPS, Q4 2025 earnings at $2.55 EPS, FY2025 earnings at $9.30 EPS, Q1 2026 earnings at $2.44 EPS, Q3 2026 earnings at $2.65 EPS, Q4 2026 earnings at $2.68 EPS, FY2026 earnings at $10.22 EPS, Q1 2027 earnings at $2.65 EPS and FY2027 earnings at $10.91 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.46 EPS.

Remove Ads

CRL has been the subject of a number of other reports. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. UBS Group reaffirmed a "neutral" rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Barclays dropped their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Stock Performance

CRL stock traded down $0.58 on Friday, hitting $106.02. The company's stock had a trading volume of 2,845,037 shares, compared to its average volume of 878,892. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of 706.79, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The firm has a 50 day moving average of $155.52 and a two-hundred day moving average of $176.21. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $254.15.

Insider Activity

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of the business. Rothschild Investment LLC increased its position in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares in the last quarter. Versant Capital Management Inc increased its position in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the 4th quarter valued at about $37,000. Finally, GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).